2026-09-20T10:21:20Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/1209002026-06-17T14:46:22Zcom_1721.1_7582com_1721.1_7581col_1721.1_131022
Paula T. Hammond.
Correa, Santiago (Santiago Correa Echavarria)
Massachusetts Institute of Technology. Department of Biological Engineering.
Massachusetts Institute of Technology. Department of Biological Engineering
2019-03-11T19:36:44Z
2019-03-11T19:36:44Z
2018
2018
http://hdl.handle.net/1721.1/120900
1088894429
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, 2018.
Cataloged from PDF version of thesis.
Includes bibliographical references.
Survival rates for ovarian cancer haven't meaningfully improved in thirty years. Ovarian cancer is particularly difficult to treat because it is usually discovered after it has metastasized and it quickly develops resistance to the few drugs that are initially effective at controlling it. Nanomedicine has the potential to change the paradigm for ovarian cancer treatment by delivering complex combinations of conventional drugs plus next-generation therapies like small interfering RNA (siRNA) and immunotherapy. However, nanoparticles must be tailored to the particular drug-delivery challenges and opportunities posed by ovarian cancer. In this thesis, we designed layer-by-layer (LbL) nanoparticles (NPs) to target ovarian cancer using library-based approaches. Using this approach, we identified promising formulations for developing an advanced nanotheranostic that both treats and detects ovarian cancer. In order to develop LbL NPs for treating ovarian cancer, we identified and overcame process engineering and fundamental materials challenges, thereby improving synthesis robustness, throughput and scale. Chapter 2 describes how modern tangential flow filtration significantly improves throughput and scalability in colloidal LbL assembly. Chapter 3 implements this improved synthetic approach to generate a small library of LbL NPs that screen for tumor-targeting properties on ovarian cancer cells, both in vitro and in vivo. Our results demonstrate that ovarian cancer cells have a high affinity to carboxylated LbL NPs, and we report several tumor-targeting formulations with distinct subcellular trafficking patterns. Chapter 4 explores the role of salt in LbL colloidal assembly, and we develop strategies for robustly synthesizing LbL-modified liposomes with high loading of siRNA. Chapter 5 advances a promising formulation identified by our surface chemistry screen, which we developed into an advanced nanotheranostic device that delivers siRNA and mediates urinary-based tumor detection. Future work that continues to improve the synthesis of LbL NPs will be essential to generate larger and more ambitious LbL NP libraries. In turn, these libraries will facilitate systematic studies that further tailor the LbL platform to specific diseases and biomedical applications.
"This material is partly based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. 1122374. This material is partly based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. 1122374"--Page 187.
by Santiago Correa.
Ph.D.
249 pages
eng
Massachusetts Institute of Technology
MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.
http://dspace.mit.edu/handle/1721.1/7582
Biological Engineering.
Engineering layer-by-layer nanoparticles for the targeted delivery of therapeutics to ovarian cancer
Thesis
application/pdf
false
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="bda82907-24e1-434d-a5c7-eb1209a502f8">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Engineering layer-by-layer nanoparticles for the targeted delivery of therapeutics to ovarian cancer</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2018</PublicationDate>
<Authors>
<Author>
<DisplayName>Correa, Santiago (Santiago Correa Echavarria)</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Biological Engineering.</Keyword>
<Abstract>Survival rates for ovarian cancer haven't meaningfully improved in thirty years. Ovarian cancer is particularly difficult to treat because it is usually discovered after it has metastasized and it quickly develops resistance to the few drugs that are initially effective at controlling it. Nanomedicine has the potential to change the paradigm for ovarian cancer treatment by delivering complex combinations of conventional drugs plus next-generation therapies like small interfering RNA (siRNA) and immunotherapy. However, nanoparticles must be tailored to the particular drug-delivery challenges and opportunities posed by ovarian cancer. In this thesis, we designed layer-by-layer (LbL) nanoparticles (NPs) to target ovarian cancer using library-based approaches. Using this approach, we identified promising formulations for developing an advanced nanotheranostic that both treats and detects ovarian cancer. In order to develop LbL NPs for treating ovarian cancer, we identified and overcame process engineering and fundamental materials challenges, thereby improving synthesis robustness, throughput and scale. Chapter 2 describes how modern tangential flow filtration significantly improves throughput and scalability in colloidal LbL assembly. Chapter 3 implements this improved synthetic approach to generate a small library of LbL NPs that screen for tumor-targeting properties on ovarian cancer cells, both in vitro and in vivo. Our results demonstrate that ovarian cancer cells have a high affinity to carboxylated LbL NPs, and we report several tumor-targeting formulations with distinct subcellular trafficking patterns. Chapter 4 explores the role of salt in LbL colloidal assembly, and we develop strategies for robustly synthesizing LbL-modified liposomes with high loading of siRNA. Chapter 5 advances a promising formulation identified by our surface chemistry screen, which we developed into an advanced nanotheranostic device that delivers siRNA and mediates urinary-based tumor detection. Future work that continues to improve the synthesis of LbL NPs will be essential to generate larger and more ambitious LbL NP libraries. In turn, these libraries will facilitate systematic studies that further tailor the LbL platform to specific diseases and biomedical applications.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>